We are pleased to announce that Alentis Therapeutics, a company within our portfolio, has been granted fast track designation by the US FDA for its investigational monoclonal antibody, ALE.C04. This designation will facilitate the development of ALE.C04 for the treatment of patients with recurrent or metastatic CLDN1-positive HNSCC. The FDA’s recognition affirms the potential of ALE.C04 to address a significant unmet medical need. The current Phase 1/2 clinical trial of ALE.C04 is expected to provide valuable data on its safety, efficacy, and therapeutic profile. Alentis Therapeutics continues its dedicated work in targeting CLDN1 on cancer cells, aiming to provide innovative treatment options for patients.
